Biopharmaceutical company Galena Biopharma has announced patent notification from the European Patent Office for pharmaceutical use of NeuVax (nelipepimut-S) as a vaccine for the prevention of relapse in breast cancer patients. The patent ...
Tags: Galena Biopharma, Neuvax
Galena Biopharma and Leica Biosystems have joined forces to develop a companion diagnostic for Galena's NeuVax(nelipepimut-S or E75),a breast cancer therapeutic. As part of the partnership,Leica's Bond Oracle HER2 IHC System companion ...
Galena Biopharma has reported a net loss of $6.26m, or $0.09 per share, for the third quarter ended 30 September 2012 compared to a net loss of $5.47m, or $0.09 per share, for the third quarter ended 30 September 2011. Operating loss for ...
Tags: Net Loss, operational and business development, patient enrollment
The US Patent and Trademark Office (USPTO) has issued a key patent covering the use of Galena Biopharma's NeuVax for inducing immunity to breast cancer recurrence in patients having low-to-intermediate IHC levels of 1+ or 2+ and a FISH ...